Skip to content

Evaluation of the effect and strategy of BCG replanting

Evaluation of the effect and strategy of BCG replanting

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076041
Enrollment
Unknown
Registered
2023-09-22
Start date
2023-10-01
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

Experimental group 1:BCG Vaccination or BCG Re-vaccination
Screening:Tuberculin skin test

Sponsors

The Eighth Medical Center of PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
15 Years to 34 Years

Inclusion criteria

Inclusion criteria: 1 Students in University 2 Males 3 Aged between 15-40

Exclusion criteria

Exclusion criteria: 1 People with Allergy 2 People with fever, infectious diseases during the program 3. Patients with active tuberculosis, patients currently undergoing tuberculosis treatment and patients with old tuberculosis; 4. Patients with abnormal liver function, diabetics, and patients with immune system diseases (such as HIV); 5. Patients with severe chronic diseases (such as heart, brain, vascular diseases, chronic kidney diseases); 6. Suffering from encephalopathy, uncontrolled epilepsy and other progressive neurological diseases; 7. Suffering from severe eczema or other skin diseases.

Design outcomes

Primary

MeasureTime frame
Absolute lymphocyte subsets count;Cellular multifactor assays;

Countries

China

Contacts

Public ContactJingli Du

The Eighth Medical Center of PLA General Hospital

dujingli2006@sohu.com+86 136 4121 7501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026